This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Myocarditis and Pericarditis Following the SARS-CoV-2 Infection and COVID-19 Vaccination (preprint)
preprints.org; 2023.
Preprint
in English
| PREPRINT-PREPRINTS.ORG | ID: ppzbmed-10.20944.preprints202302.0085.v1
ABSTRACT
Cardiac complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been well-identified since the beginning of the current coronavirus disease 2019 (COVID-19) pandemic. Such conditions can occur of various etiologies, such as respiratory failure and hypoxemia, direct cardiac tissue damage due to viral replication, indirect myocarditis as systemic inflammation, and the interaction of different medications. Recently, with the start of the COVID-19 vaccination programs, COVID-19 vaccine-associated cardiac adverse events (AEs) have emerged and are increasingly being reported. Although these AEs are usually mild and self-limited, they can sometimes cause severe, catastrophic outcomes. This review compares the pathophysiology, diagnosis, and treatment of the de novo SARS-CoV-2 infection-related and COVID-19 vaccine-related myocarditis and pericarditis.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-PREPRINTS.ORG
Main subject:
Pericarditis
/
Respiratory Insufficiency
/
Coronavirus Infections
/
COVID-19
/
Inflammation
/
Hypoxia
/
Myocarditis
Language:
English
Year:
2023
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS